U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.

Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.

The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.


Contact the Combat COVID Monoclonal Antibodies Call Center:


Our bodies naturally make antibodies to fight infection. mAbs are made in a lab and given to people directly through an intravenous (IV) infusion. To find more information about current mAb treatment, visit https://www.phe.gov/emergency/events/COVID19/therapeutics/Pages/updates.aspx

mAb treatments authorized by the U.S. Food and Drug Administration (FDA) for emergency use may help people who are at high risk for serious symptoms of the disease to:

a) Reduce the likelihood of staying in the hospital.

b) Recover faster from COVID-19.

mAbs are available for people who:

  1. Are at high risk of becoming seriously ill. To learn more, visit our page Who is at High Risk for Serious COVID-19?
  2. Have tested positive for COVID-19 and have mild to moderate symptoms of the disease for 10 days or less
  3. Have been recently exposed to someone who has tested positive for COVID-19 and are at high risk for serious COVID-19

mAb treatment must be given within 10 days of a person’s first symptoms of COVID-19 or having been exposed to someone who has tested positive for COVID-19. The sooner a person receives mAb treatment, the better.

mAb treatments are still being studied. However, they have received Emergency Use Authorization (EUA) from the FDA and more than 600,000 people have been treated with mAbs. Researchers continue to study mAb treatments for safety and effectiveness.

Three mAb treatments have received EUA from the FDA for people who are not in the hospital: REGEN-COVTM (casirivimab and imdevimab)bamlanivimab and etesevimab, and sotrovimab. All treatments are given as either an IV infusion or a series of shots.

Actemra is also a mAb that has also been issued an EUA from the FDA. It can only be given to people in the hospital with worse COVID-19 symptoms.

The three treatments offered to people who are not in the hospital are designed in a very similar way, with the same goal: to prevent the virus that causes COVID-19 from entering human cells.

The treatments are offered at thousands of infusion locations across the United States. These include infusion centers, urgent care clinics, and emergency rooms.

Different infusion locations have different amounts of the treatments and staff to give it available, so some locations may not be administering mAb treatments or may have limited stock of them. Your healthcare professional can help you find a location near you and can contact the infusion location to refer you for treatment.

You can learn more about mAb treatments on our page What Are Monoclonal Antibodies?

If you think you may qualify for mAb treatments and want to ask about getting treatment, contact your healthcare professional or call 1-877-332-6585 (English) and 1-877-366-0310 (Spanish) for more information.

Your healthcare professional may decide you do not qualify for mAb treatment. There could be several reasons for this. You may not meet all of the eligibility criteria or you may have an underlying health condition that disqualifies you for mAb treatment.

Whatever the reason is, do not give up. There may be other treatment options or you may be able to join a clinical trial for COVID-19.

Participants in clinical trials may receive new drugs or other treatments so researchers can evaluate how well the treatments work. Thousands of participants in clinical trials have helped with the discovery of new treatments for COVID-19. Many more participants are needed to ensure that treatments work for people of all ages, genders, races, and ethnicities.

Ask your healthcare professional if you may be eligible for a clinical trial for treating COVID-19. To learn more about clinical trials:

Call 877-414-8106 COVID-19 clinical trials